Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Philip D. Greenberg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3812-647X; OpenAlex author ID A5030463228, A5160288521. Sources: funder_awards.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
17
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper, 1 grant · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2-deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2026-015489↗
  2. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Co-author DOI 10.1126/science.adk3487↗
  3. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. Last author DOI 10.1136/jitc-2021-003525↗
  4. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-18-0448↗
  5. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-16-0322↗
  6. Pancreatic Cancer: Planning Ahead for Metastatic Spread. First author DOI 10.1016/j.ccell.2016.05.013↗
  7. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2015.09.022↗
  8. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Co-author DOI 10.1136/gutjnl-2013-306271↗

Grants 1

  1. Targeting PDA with T-Cells Engineered to Express a Mesothelin-Specific TCR AWARD pancan:2016-philip-greenberg-md-targeting-pda-with-t-cells-engineered-to

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingunn M. Stromnes · 7 shared papers, 2014–2026 · strength 0.78
  2. Sunil R. Hingorani · 6 shared papers, 2014–2026 · strength 0.66
  3. Adam L. Burrack · 3 shared papers, 2019–2026 · strength 0.47
  4. Zoe C. Schmiechen · 1 shared paper, 2026 · strength 0.23
  5. David Masopust · 1 shared paper, 2026 · strength 0.23
  6. Grant H. Hickok · 1 shared paper, 2026 · strength 0.23
  7. Paolo Provenzano · 1 shared paper, 2026 · strength 0.23
  8. Alexander K. Tsai · 1 shared paper, 2026 · strength 0.23
  9. Guhan Qian · 1 shared paper, 2026 · strength 0.23
  10. Zackery A. Ely · 1 shared paper, 2025 · strength 0.17
  11. Steven A. Carr · 1 shared paper, 2025 · strength 0.17
  12. Srivatsan Raghavan · 1 shared paper, 2025 · strength 0.17
  13. William A. Freed-Pastor · 1 shared paper, 2025 · strength 0.17
  14. Andrew J. Aguirre · 1 shared paper, 2025 · strength 0.17
  15. Brian Matthew Wolpin · 1 shared paper, 2025 · strength 0.17
  16. James M. Cleary · 1 shared paper, 2025 · strength 0.17
  17. Tyler Jacks · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.